Ivo de Vos

DAD, YOU ROCK!

Spotlight: A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer by @IvodeVos , Annick Meertens et al Watch all our Spotlights here: buff.ly/4fyQjDG #Spotlight #UroSoMe #MedTwitter

Check out this detailed 21-year follow-up on the impact of PSA-based screening on #ProstateCancer morbidity and mortality from the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer #ERSPC > bit.ly/463okHx @IvodeVos @MoniqueRoobol

Check out this detailed 21-year follow-up on the impact of PSA-based screening on #ProstateCancer morbidity and mortality from the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer #ERSPC > bit.ly/463okHx @IvodeVos @MoniqueRoobol

🎯After 21 yrs in Rotterdam PCa screening study: Invite 246, diagnose 14 to prevent 1 death. Invite 121, diagnose 7 to prevent 1 metastatic case. Overdiagnosis now strongly reduced (risk stratification, MRI etc). Let's bring this advantage to all men who may benefit! @uroweb

Presented at #EAU23: In men with prostate cancer on PSA screening, radical treatments led to half the incidence of metastasis and local progression as active monitoring without affecting disease-specific or overall survival (ProtecT trial) nej.md/3Yvyn2V #oncology

Current Issue: Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the EAU Guidelines Using Long-term Data from the EU Randomised Study of Screening for PCa Rotterdam buff.ly/3PvrB8Q @IvodeVos @SRemmers92 @MoniqueRoobol